Cranial vascular effects of zolmitriptan, a centrally active 5-HT(1B/1D) receptor partial agonist for the acute treatment of migraine

European Journal of Pharmacology

Volumn 361, Issue 2-3, 1998, Pages 191-197

  MacLennan, Stephen J ^a   Cambridge, David ^a   Whiting, Mark V ^a   Marston, Chris ^a   Martin, Graeme R ^a  

^a WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

5 HT(1B 1D) receptor agonist; Cranial blood flow distribution; Migraine; Sumatriptan; Zolmitriptan

Indexed keywords

MICROSPHERE; PARTIAL AGONIST; SEROTONIN AGONIST; ZOLMITRIPTAN;

ANIMAL EXPERIMENT; ARTERIOVENOUS FISTULA; ARTERY BLOOD FLOW; ARTICLE; BRAIN BLOOD FLOW; CAT; CONDUCTANCE; CONTROLLED STUDY; DOG; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LASER DOPPLER FLOWMETRY; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY;

ANIMALS; ARTERIOVENOUS ANASTOMOSIS; BLOOD FLOW VELOCITY; CAROTID ARTERIES; CATS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOGS; MALE; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0032553688     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00727-4     Document Type: Article

References (40)

1. Bates D., Ashford E., Dawson R., Ensink F.B., Gilhus N.E., Olesen J., Pilgrim A.J., Shevlin P. Subcutaneous sumatriptan during the migraine aura. Neurology. 44:1994;1587-1592. Sumatriptan Aura Study Group.
2. Buzzi M.G., Moskowitz M.A. The trigeminovascular system and migraine. Pathol. Biol. 40:1992;313-317.
3. Caekebeke J.F., Ferrari M.D., Zwetsloot C.P., Jansen J., Saxena P.R. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology. 42:1992;1522-1526.
4. 1-like receptors mediating vasoconstriction and vasodilatation: their characterisation and distribution in the intact canine cardiovascular system. Br. J. Pharmacol. 114:1995;961-968.
5. 1-like receptor agonist. Br. J. Pharmacol. 96:1989;379-387.
6. 1-like receptor agonist, on pial vessel diameter in anaesthetised cats. J. Cereb. Blood Flow Metab. 12:1992;514-519.
7. Den Boer M.O., Somers J.A., Saxena P.R. Lack of effect of the antimigraine drugs, sumatriptan, ergotamine and dihydroergotamine on arteriovenous anastomotic shunting in the dura mater of the pig. Br. J. Pharmacol. 107:1992;577-583.
8. Diener, H.C., May, A., 1996. Positron emission tomography studies in acute migraine attacks. In: Sandler, M., Ferrari, M., Harnett, S. (Eds.), Migraine: Pharmacology and Genetics. Chapman & Hall, London, pp. 109-116.
9. 1D agonist, prevent migraine headache when taken during an aura? Eur. Neurol. 36:1996;28-31. (Suppl. 2).
10. Earl N.L. Clinical safety of zolmitriptan: aggregated data from patients and volunteers to date. Eur. Neurol. 36:1996;8-12. Suppl. 2.
11. Feniuk W., Humphrey P.P.A., Perren M.J. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. Br. J. Pharmacol. 96:1989;83-90.
12. Ferrari M.D. The clinical effectivness of zolmitriptan in the acute treatment of migraine. Eur. Neurol. 36:1996;4-7. Suppl. 2.
13. Ferrari M.D., Haan J., Blokland J.A.K., Arndt J.W., Minee P., Zwinderman A.H., Pauwels E.K.J., Saxena P.R. Cerebral blood flow during migraine attacks without aura and effect of sumatriptan. Arch. Neurol. 52:1995;135-139.
14. Friberg L., Olesen J., Iversen H.K., Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet. 338ii:1991;13-17.
15. Geraud G.E.A. Evaluation of the long-term safety and efficacy of zolmitriptan in the treatment of migraine. Eur. Neurol. 36:1996;24-27. (Suppl. 2).
16. Goadsby P.J., Edvinsson L. The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33:1993;48-56.
17. Goadsby P.J., Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5-HT)-1D receptor agonist zolmitriptan. Headache. 34:1994;394-399.
18. Goadsby P.J., Hoskin K.L. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5-HT) 1B/1D receptor agonist 311C90 (zolmitriptan). Are brainstem sites a therapeutic target in migraine? Pain. 67:1996;355-359.
19. Goadsby P.J., Knight Y. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia. 17:1997;153-158.
20. Goadsby P.J., Zagami A.S., Lambert G.A. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache. 31:1991;365-371.
21. Green, C.J., 1979. Animal Anaesthesia. Laboratory Animals Handbooks 8. Laboratory Animals, London.
22. Humphrey P.P.A., Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol. Sci. 12:1991;444-446.
23. Humphrey P.P.A., Goadsby P.J. The mode of action of sumatriptan is vascular? A debate. Cephalalgia. 14:1994;401-410.
24. Kaube H., Hoskin K.L., Goadsby P.J. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br. J. Pharmacol. 109:1993;788-792.
25. Klein K.B. Zolmitriptan, a new acute treatment for migraine: an efficacy overview. Cephalalgia. 15:1995;175. (Suppl. 14).
26. Markowitz S., Saito K., Moskowitz M.A. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalagia. 8:1988;83-91.
27. 1D receptor agonist zolmitriptan. In: Clifford Rose, F. (Ed.), New Advances in Headache Research, Vol. 4. Smith-Gordon, Nishimura, pp. 3-4.
28. 1D agonist drugs: selectively targeting additional sites of action. Eur. Neurol. 36:1996;13-18. (Suppl. 2).
29. 1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br. J. Pharmacol. 121:1997;157-164.
30. Monstad I., Krabbe A., Micieli G., Prusinski A., Cole J., Pilgrim A., Shevlin P. Preemptive oral treatment with sumatriptan during a cluster period. Headache. 35:1995;607-613.
31. Moskowitz M.A. The neurobiology of vascular head pain. Ann. Neurol. 16:1984;157-168.
32. Moskowitz M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci. 13:1992;307-311.
33. Mylecharane, E.J., Phillips, C.A., 1989. Mechanisms of 5-hydroxytryptamine-induced vasodilatation. In: Fozard, J.R. (Ed.), The Peripheral Actions of 5-Hydroxytryptamine. Oxford Univ. Press, Oxford, pp. 147-181.
34. Page I.H., McCubbin M.D. The variable arterial pressure response to serotonin in laboratory animals and man. Circ. Res. 1:1953;354-362.
35. 1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br. J. Pharmacol. 96:1989;434-449.
36. Perren M.J., Feniuk W., Humphrey P.P.A. The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia. 9:1989;41-46. (Suppl. 9).
37. Proietti-Cecchini A., Afra J., Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia. 17:1997;849-854.
38. Saxena P.R., Verdouw P.D. Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J. Physiol. 332:1982;501-520.
39. Spierings E.L.H., Saxena P.R. Antimigraine drugs and cranial arteriovenous shunting in the cat. Neurology. 30:1980;696-701.
40. Zwetsloot C.P., Caekebeke J.F., Ferrari M.D. Lack of asymmetry of middle cerebral artery blood velocity in unilateral migraine. Stroke. 24:1993;1335-1338.